Multivariate analyses identified a set of five shared features that predicted protection across both Vi-TT and Vi-PS vaccine groups at day 28: Vi IgA quantity (detected using the binding antibody multiplex assay [BAMA]; Dahora et al., 2019), Vi IgG2 titer (measured using ELISA), and IgA2 avidity were associated with protection, whereas ADNKA features (release of IFNγ and macrophage inflammatory protein-1β [MIP-1β]) were associated with infection (Fig. 5, A and B). The gene discussed is CCL4; the disease is infection.